More
Americans die from lung cancer than any other type of cancer. The CDC reports
that in 2011, out of the 207,339 Americans diagnosed with lung cancer, 156,953
people died from the disease. Science is advancing screen cancer screening
technology, though current methods unarguably have room for improvement.
Mortality
rates were reduced by 20% in patients that underwent screening with low-dose
computed tomography (CT) compared to radiographic screening, according to the
National Institutes of Health. Despite the effectiveness and benefits of CT
screening, this method carries a higher risk of false-positive results and
unnecessary invasive procedures compared to X-ray screening, though the latter
method is no longer recommended for screening.
Healthcare
technology innovator Zenosense is developing an alternative that the company
believes has the potential to meet or exceed the accuracy of CT scanning
without risk and at a lower cost. Zenosense’s development partner, Zenon
Biosystem (“Zenon”), is currently manufacturing two pre-commercial prototypes
of a screening device that analyzes a person’s breath to detect lung cancer.
Here’s why
it could work. Numerous scientific studies suggest that lung cancer alters
cellular metabolism, resulting in the production of a number of distinctive
Volatile Organic Compounds (VOCs) in exhaled breath. Zenosense’s device filters
out VOCs NOT of interest to optimize the detection of target VOC biomarkers
that are associated with the incidence of lung cancer.
When
manufacturing is complete, Zenosense plans to conduct a lung cancer detection
trial to be carried out in a clinical setting using two of the devices of the
same design to ensure reproducibility of results. Clinical tests will examine
400 subjects split into four groups to include smokers, non-smokers, and those
suffering from lung cancer and chronic obstructive pulmonary disease (COPD).
A
preliminary commercial target for Zenosense will be to establish whether its
device can meet or exceed the accuracy of low-dose CT scanning to detect early
stage lung cancer, which currently is the only realistic method for mass
screening. The company anticipates completing its manufacturing later this
month.
For more
information, visit www.zenosense.net
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment